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ABSTRACT
Changes in susceptibility to treatment with Cytoxan, metho-
trexate, 5-fluorouracil, and Adriamycin, single or in combina
tion, have been studied during the initial and progressive stages
of s.c. and pulmonary (via tail vein injection) growth of two
transplanted syngeneic C3H/He mammary carcinomas. One
tumor was fast growing, reaching a size of 3 mm from a 1-mm
s.c. implant in 7 days; the second tumor would grow to the
same size in 30 days. The tumor with the slower growth rate
was more susceptible to drug treatment, manifested by delayed
growth as well as by prevented growth. The slower-growing
tumor also remained susceptible longer, when treatment was
delayed, than did the faster-growing tumor. Pulmonary growth
was more often prevented by drug treatment than was s.c.
growth. Tumor implants s.c. which had reached palpable size
could be reduced temporarily to impalpable size by effective
drug treatment but were rarely cured. The importance of early
treatment relative to the time of tumor implantation was indi
cated when early treatment with a single drug proved more
effective than did delayed treatment with a more potent com
bination of drugs.
INTRODUCTION
The fundamental rationale for adjuvant or prophylactic treat
ment of cancer derives from in vivo and in vitro studies of tumor
cell kinetics which have demonstrated the following: (a) growth
curves for most experimental neoplastic cells have a Gom-
pertzian function; (b) the highest mitotic index is associated
with the least-crowded conditions; (c) small tumor masses with
high mitotic indexes are most sensitive to S-phase-specific
drugs; and (d) the smaller the experimental tumor, the greater
will be its potential curability by drug treatment (10, 12-14).
The results of clinical studies (1, 4) have indicated that subsets
of postmastectomy patients differ significantly with respect to
the benefits derived from adjuvant chemotherapy and invite
guarded optimism.
A variety of drugs effective against mouse mammary tumors
have been described (9). Many of these are also active against
human breast cancer when used against clinically established
mÃ©tastases(2). Some experimental studies have reported that
surgical removal of the primary tumor followed by drug treat
ment reduced the number of expected mÃ©tastases(6, 11). In
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other studies, systemic chemotherapy following excision of the
primary tumor reduced the growth of local recurrence without
affecting the incidence of mÃ©tastases(5). Several investigators
have also reported that drug therapy may facilitate metastatic
growth (7, 14, 15). Fefer (3) found the net result of drug
treatment to be a prolonged survival of murine tumor hosts.
Apparently, it is not yet safe to predict the outcome of drug
treatments even in experimental tumor systems.
Because the effectiveness of drug treatment (8), like the
effectiveness of immune resistance (16, 17), appears to be
reduced by increasing mass of malignant tissue (but is less
affected by its dissemination), both the growth rate of the tumor
and the timing of the initiation of drug treatment may be
variables in the effectiveness of adjuvant chemotherapy. The
study reported here has used a fast-growing and a slow-grow
ing mouse mammary carcinoma to investigate the relationship
of the time of s.c. and i.v. tumor implantation to the effective
ness of drug treatment.
MATERIALS AND METHODS
Mice. The tumor donors were pedigree breeding C3H/He
mice, bred from the age of 8 weeks and removed from breeding
at the appearance of the first mammary tumor or after the fifth
litter. The experimental mice were 10- to 12-week-old females
produced in full sib-mated line breeding of C3H/He mice. All
the mice were from the defined-flora, pathogen-free breeding
colony (mice carrying only the following nonpathogenic enteric
bacteria: Clostridium sp., Peptostreptococcus sp., Bacillus sp.,
and Bacteroides sp.) maintained by the Department of Cancer
Therapy Development at Pondville Hospital.
Tumors. The mammary carcinomas had developed sponta
neously in multiparous C3H/He mice and had been serially
transplanted in syngeneic virgin female mice. Tumor tissue
from the first transplant generation had been stored in liquid
N2, and the tumors were used to the sixth transplant generation
before being started again from the frozen generation 1. Tumor
tissue was removed from freshly killed or live anesthetized
donor animals, and one 1-cu mm piece of living tumor tissue
was implanted s.c. in the right flank of each host animal to
initiate new growth. Tumors from treated animals were never
used.
Tumor 38-5 was the fifth spontaneous mammary carcinoma
removed from C3H/He mouse 38. It had been shown in re
peated tests (19) to be fast growing s.c. (from a 1-mm implant
to 3 mm in 7 days) and to be immunologically neutral in
transplantation tests; i.e., the cured hosts of Tumor 38-5 dis
played neither resistance against nor stimulation of the growth
of reimplants of the same tumor. Tumor 93-2 was slow growing
s.c. (from 1-mm implant to 3 mm in 30 days) and was neutral
in transplantation tests (19).
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Chart 1. The effect of drug treatments on the pulmonary (via
tail vein) growth (A) and s.c. growth (8) of the fast-growing Tumor
38-5. Each animal was implanted both i.v. and s.c. The mice
received the following treatments: Groups 1 and 2, Cytoxan, 100
mg/kg/week for 4 weeks; Groups 3 and 4, methotrexate, 50
mg/kg/week for 4 weeks; Groups 5 and 6, 5-FUra, 50 mg/kg/
week for 4 weeks; Groups 7 and 8, all 3 drugs combined for 4
weeks; Group 9, placebo for 4 weeks. Arrows, injection sched
ules. Each group contained 5 mice. Numbers along the curves in
B, number of mice with s.c. growth.
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Tumor Implantation. Disruption of tumor tissue to obtain
suspensions of dispersed cells was accomplished with the use
of 105 mesh polyester cloth (HC-1-105 screen cloth; TETKO,
Inc., Elmsford, N. Y.) by a mechanical procedure described in
previous publications (17, 18). The s.c. (105 viable cells) and
i.v. (3 x 104 viable cells) challenge implantation of treated and
control mice were by injection of viable (trypan blue-negative)
tumor cells suspended in culture medium (Roswell Park Me
morial Institute Tissue Culture Medium 1640; Associated
Biomedics, Buffalo, N. Y.) and consisting predominantly of
single cells. The proportion of trypan blue-negative cells in the
tumor cell suspensions was usually about 20%. The challenges
were completed as soon as possible with cells from the same
suspension, which was kept on ice to delay cell clumping.
In each of the experiments, the mice were given injections(the day of tumor challenge designated as Day 0) of 105 living
tumor cells s.c. at the left shoulder and, at the same time, given
i.v. injections via the tail vein of 3 x 10" cells. Following
injection of tumor cells into the tail vein, tumor growth was
found only in the lungs. The incidence of tumors at the s.c.
injection site was checked twice weekly on the same day in all
groups of each experiment. By measuring 2 bisecting diame
ters of each tumor and using only the lesser to express tumor
size, the possible error of measuring the added diameters of
more than one focus of growth along the needle path of
injection was avoided. The tumors were excised with wide
margins when they were close to 10 mm in diameter. Tumors
that had reached this size were recognized as treatment-fail
ures and had to be removed to keep the mice alive and healthy
for the anticipated but slower development of tumors in the
lungs. Frequent examination of the mice for signs of dyspnea
decided the termination time for each animal. The mice were
killed by asphyxiation in 100% CO? gas, and the lungs were
examined for extent of tumor growth. The mice which had not
developed pulmonary symptoms werÂ»killed and examined 140
days after the challenge. Because every untreated mouse in
these experiments developed both s.c. and pulmonary tumor
growth, treated mice which were negative at 140 days were
considered to have been successfully treated.
Treatment. The experimental animals were given 4 weekly
i.p. injections of the following drugs, individually or in combi
nation: Cytoxan (cyclophosphamide monohydrate, courtesy of
Mead Johnson Research Center, Evansville, Ind.), 100 mg/kg;
methotrexate, RNX-0396 (courtesy of Lederle Laboratories,
Pearl River, N. Y.), 25 or 50 mg/kg; Adriamycin (doxorubicin
hydrochloride; courtesy of Adria Laboratories, Inc., Wilming
ton, Del.), 5 mg/kg; 5-FUra,4 (Ro2-9757; courtesy of Hoffman-
La Roche Inc., Nutley, N. J.), 25 or 50 mg/kg.
RESULTS
Drug Treatment of a Fast-growing Tumor. Chart 1 shows
the results of a test with the fast-growing Tumor 38-5 in which
drugs were given singly or in combination. The results show
that the growth of s.c. implants was not prevented by treat
ments with Cytoxan, methotrexate, or 5-FUra, used singly or in
combination. Each drug tested produced only a delay in the
growth of the s.c. tumors, particularly when given in combina-
* The abbreviation used is: 5-FUra, 5-fluorouracil.
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Chart 2. The effect of drug treatments on the pulmonary
(via tail vein) growth (A) and the s.c. growth (B) of the fast-
growing Tumor 38-5. Each animal was implanted both i.v. and
s.c. The mice received the following treatments: Groups 1 to
6, 3 drugs in combination (Cytoxan, 100 mg/kg/week for 4
weeks, plus methotrexate, 25 mg/kg/week for 4 weeks, plus
5-FUra, 25 mg/kg/week for 4 weeks); Group 7, placebo for
4 weeks. Arrows, injection schedules. Each group contained
5 mice. Numbers along the curves in B, number of mice with
s.c. growth.
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Chart 3. The effect of drug treatments on the pulmonary (via tail
vein) growth (A) and the s.c. growth (ÃŸ)of the fast-growing Tumor
38-5. Each animal was implanted both i.v. and s.c. The mice received
the following treatments: Groups 1 and 2, Cytoxan, 100 mg/kg/week
for 4 weeks: Groups 3 and 4, Adriamycin, 5 mg/kg/week for 4
weeks; Groups 5 and 6, both drugs combined for 4 weeks; Group 7,
placebo for 4 weeks. Arrows, injection schedules. Each group con
tained 5 mice. Numbers along the curves in B. number of mice with
s.c. growth.
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Chart 4. The effect of drug treatments on the pulmonary (via tail vein) growth (A) and the s.c. growth (6) of the slow-growing Tumor 93-2. Each animal was
implanted both i.v. and s.c. The mice received the following treatments: Groups 1 and 2, Cytoxan, 100 mg/kg/week for 4 weeks; Groups 3 and 4, methotrexate, 50
mg/kg/week for 4 weeks; Groups 5 and 6, 5-FUra, 50 mg/kg/week for 4 weeks; Groups 7 and 8, all 3 drugs combined for 4 weeks; Group 9. placebo for 4 weeks.
Groups 1 to 8 contained 5 mice each; Group 9 contained 10 mice. Numbers along the curves in B, numbers of mice with s.c. growth.
tion, and particularly when given from the day of challenge.
The results of i.v. tumor challenge show that treatment with all
3 drugs from the day of challenge prevented pulmonary growth
in 4 of 5 mice in Group 7. The same treatment, delayed 5 days
in Group 8, prevented pulmonary growth in only 1 of 5 mice.
Cytoxan alone, given from the day of challenge, prevented
pulmonary growth in 2 of 5 mice.
Chart 2 shows the results of a test with Tumor 38-5 in which
the treatment with Cytoxan, methotrexate, and 5-FUra was
started at progressively later times following s.c. and i.v. chal
lenge. Treatments were started: (a) on the day of challenge;
(b) 5 days after challenge; (c) on day 12 with s.c. tumors at a
size of 2 or 3 mm; (d) on Day 16 with tumors at a size of 4 mm;
and (e) on Day 19 with s.c. tumors at a size of 5 mm. The
results show that the treatment succeeded only in delaying the
s.c. tumor growth, with the greatest effect when treatment was
started on the day of challenge. The greatest effect against
pulmonary growth was also achieved when the treatment was
started on the day of challenge; a delay of 5 days increased
pulmonary growth from 0 of 5 mice to 3 of 5 mice. Pulmonary
growth was not prevented when treatment was started 12 or
more days after challenge.
Chart 3 shows the results of a test with Tumor 38-5 in which
the treatment with Cytoxan and Adriamycin, singly or com
bined, was started on the day of i.v. and s.c. challenge or 5
days after challenge. The results show that early combined
treatment with Cytoxan and Adriamycin was most effective
both in delaying s.c. growth and in preventing pulmonary
growth. The figures also show that early treatment with Cytoxan
alone gave better results against both s.c. and pulmonary
growth than did delayed treatment with the more potent com
bination of Cytoxan and Adriamycin.
Drug Treatment of a Slow-growing Tumor. The slow-grow
ing Tumor 93-2 was tested in the same way as the fast-growing
Tumor 38-5 (see Chart 1), using the same drug treatments and
following the same schedule. Chart 4 shows that combined
treatment from Day 0 or from Day 5 with Cytoxan, methotrex
ate, and 5-FUra, prevented both s.c. and pulmonary tumor
growth in all the mice. Early treatment with Cytoxan alone also
prevented pulmonary tumor growth, but prevented s.c. growth
in only 1 of 5 mice. Delayed treatment with Cytoxan was as
effective as early treatment with 5-FUra, pulmonary tumor
growth being prevented in 1 of 5 mice in each group.
Chart 5 shows the results of a test with Tumor 93-2, similar
to the test presented in Chart 2. The results show that combined
treatment with Cytoxan, methotrexate, and 5-FUra was com
pletely effective against the growth of pulmonary tumors even
if treatment was started as late as Day 26 after challenge and
that it could still prevent pulmonary tumors in 3 of 5 mice when
treatment was started on Day 28. Growth s.c. was less readily
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Chart 5. The effect of drug treatments on the pulmonary (via tail vein) growth (A) and the s.c. growth (B) of the slow-growing Tumor 93-2. Each animal was
implanted both i.v. and s.c. The mice received the following treatments: Groups 1 to 6, 3 drugs in combination (Cytoxan, 100 mg/kg/week for 4 weeks, plus
methotrexate. 25 mg/kg/week for 4 weeks, plus 5-FUra, 25 mg/kg/week for 4 weeks); Group 7, placebo for 4 weeks. Arrows, injection schedules. Groups 1 to 6
contained 5 mice each; Group 7 contained 10 mice Numbers along the curves in B, number of mice with s c. growth.
controlled; only 1 of 5 palpable tumors was cured after treat
ment was started on Day 26 (Chart 5B, Group 3). Treatments
started on Days 0 and 5 were completely effective in preventing
s.c. as well as pulmonary growth.
Chart 6 shows the results of a test with Tumor 93-2, in which
the treatment with Cytoxan and Adriamycin, singly or com
bined, was started (like the test shown in Chart 3) on the day
of i.v. and s.c. challenge or 5 days after challenge. The results
show that early combined treatment with Cytoxan and Adria
mycin was more effective in delaying and preventing pulmonary
and s.c. tumor growth than either drug given alone. The com
bined drug treatment was very effective against this slow-
growing tumor, giving better results even when delayed to Day
5 than did treatment with Cytoxan started on Day 0.
DISCUSSION
The results of the investigation reported here suggest that
there was a period of relatively greater susceptibility to drug
treatment during the early phase of tumor establishment when
cures could be achieved. Of 2 mammary carcinomas with
different growth rates, 38-5 and 93-2, it was Tumor 93-2, with
the slowest growth rate, which was more controllable, presum
ably because it remained longer in a susceptible growth phase.
Once either tumor had reached palpable s.c. growth, they
could be reduced temporarily by effective drug treatment to
impalpable size (Chart 36, Group 6 Chart 58, Group 3) but,
with the exception of one case (Chart 56, Group 3) could not
be cured. However, the longer latency of tumors in treated
mice measured from the last injection of drugs compared to
the latency of tumors in control mice measured from Day 0
[e.g. Group 1 versus Group 7 (Chart 26)] suggests that the
treatment had reduced the original s.c. inoculum of 105 viable
cells to a much lower number and may have come close to
eliminating the implants.
For reasons that cannot yet be explained, the drug treat
ments more effectively prevented the growth of tumor cells
implanted in the lungs than tumor cells implanted in the loose
connective tissue of the skin. It may be that the drugs injected
i.p. were more readily and more abundantly available where
blood-borne tumor cells lodged and were, therefore, more
effective. Since it has also been found that implanted C3H/He
mammary carcinomas invariably grow slower in the lungs than
s.c. (19), they could possibly have remained longer in an
unestablished, susceptible growth phase. Whatever the reason
for the observed effect, it is encouraging that malignant growth,
under conditions that simulate venous dissemination, has a
growth phase which is particularly susceptible to chemother
apy.
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Chart 6. The effect of drug treatments on the pulmonary (via tail vein) growth (A) and s.c. growth (B) of the slow-growing Tumor 93-2. Each animal was implanted
both i.v. and s.c. The mice received the following treatments: Groups 1 and 2, Cytoxan, 100 mg/kg/week for 4 weeks; Groups 3 and 4, Adriamycin, 5 mg/kg/week
for 4 weeks; Groups 5 and 6. both drugs combined for 4 weeks; Group 7. placebo for 4 weeks. Arrows, injection schedules. Groups 1 to 6 contained 5 mice each;
Group 7 contained 10 mice. Numbers along the curves in B, number of mice with s.c. growth.
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